JPS6237636B2 - - Google Patents

Info

Publication number
JPS6237636B2
JPS6237636B2 JP56018865A JP1886581A JPS6237636B2 JP S6237636 B2 JPS6237636 B2 JP S6237636B2 JP 56018865 A JP56018865 A JP 56018865A JP 1886581 A JP1886581 A JP 1886581A JP S6237636 B2 JPS6237636 B2 JP S6237636B2
Authority
JP
Japan
Prior art keywords
compounds
formula
compound
pharmaceutically acceptable
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP56018865A
Other languages
English (en)
Japanese (ja)
Other versions
JPS56127379A (en
Inventor
Saajesu Reinhaado
Kooren Shunuu Rodonii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Original Assignee
PFIZER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER filed Critical PFIZER
Publication of JPS56127379A publication Critical patent/JPS56127379A/ja
Publication of JPS6237636B2 publication Critical patent/JPS6237636B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP1886581A 1980-02-12 1981-02-10 Hydantoin amine compound Granted JPS56127379A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/120,944 US4248882A (en) 1980-02-12 1980-02-12 Treating diabetes-associated complications with hydantoin amines

Publications (2)

Publication Number Publication Date
JPS56127379A JPS56127379A (en) 1981-10-06
JPS6237636B2 true JPS6237636B2 (2) 1987-08-13

Family

ID=22393428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1886581A Granted JPS56127379A (en) 1980-02-12 1981-02-10 Hydantoin amine compound

Country Status (8)

Country Link
US (1) US4248882A (2)
EP (1) EP0034063B1 (2)
JP (1) JPS56127379A (2)
AT (1) ATE3865T1 (2)
DE (1) DE3160449D1 (2)
DK (1) DK156400C (2)
GR (1) GR73856B (2)
IE (1) IE50895B1 (2)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU532110B2 (en) * 1979-11-13 1983-09-15 Ici Ltd. Spiro(imidazolidine-4,3:-indoline)-2,2:5-trione derivatives
EP0065393B1 (en) * 1981-05-12 1984-12-27 Imperial Chemical Industries Plc Pyrrole derivatives
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
US4474967A (en) * 1983-04-27 1984-10-02 Pfizer Inc. 8-Deutero and 8-tritio-substituted derivatives of D-4S-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione
US4464380A (en) * 1983-05-25 1984-08-07 Pfizer Inc. Imidazolidinedione derivatives
DK277484A (da) * 1983-06-23 1984-12-24 Hoffmann La Roche Thiazolidinderivater
EP0172352B1 (en) * 1984-06-22 1990-08-29 Beecham Group Plc Active benzopyran compounds
HU198212B (en) * 1984-07-20 1989-08-28 Pfizer Process for production of spiro-imidasolones
DE3565105D1 (en) * 1984-08-20 1988-10-27 Pfizer Process for the production as asymmetric hydantoins
US5340829A (en) * 1984-11-20 1994-08-23 Washington Research Foundation Immunoregulatory agents
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
JPH0772190B2 (ja) * 1985-02-26 1995-08-02 エーザイ株式会社 ヒダントイン誘導体
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications
JPS63126881A (ja) * 1986-11-14 1988-05-30 Sanwa Kagaku Kenkyusho Co Ltd ヒダントイン誘導体、その塩、これらの製法並びに該化合物を有効成分とする糖尿病合併症の予防及び治療剤
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
FI901087A0 (fi) * 1987-09-04 1990-03-02 Pfizer Azolidindionderivat.
US4952694A (en) * 1988-07-27 1990-08-28 Pfizer Inc. Novel resolution process for racemic spiro-hydantoins
WO1992000071A1 (en) * 1989-02-10 1992-01-09 Washington Research Foundation Immunoregulatory agents
JP2678499B2 (ja) * 1989-08-09 1997-11-17 日本臓器製薬 株式会社 尿毒症毒素低下剤
JPH03215435A (ja) * 1990-01-12 1991-09-20 Sanwa Kagaku Kenkyusho Co Ltd アルドース還元酵素阻害剤を主成分とする潰瘍治療剤
UA76984C2 (en) * 2001-04-05 2006-10-16 Nissan Chemical Ind Ltd A method for preparing a 7-qunolinyl-3,5-dihydroxyhept-6-enoate
US7795203B2 (en) * 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1135915B (de) * 1961-06-29 1962-09-06 Asta Werke Ag Chem Fab Verfahren zur Herstellung neuer, antikonvulsiv wirksamer Spirohydantoine
US3534037A (en) * 1968-05-10 1970-10-13 Smithkline Corp Spiro-(imidazolidine and pyrimidine-quinoline and cyclopropa(c)quinoline) compounds
US3821383A (en) * 1972-07-10 1974-06-28 Ayerst Mckenna & Harrison Compositions for and a method of treating diabetic complications
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4177282A (en) * 1977-05-23 1979-12-04 Pfizer Inc. Hydantoin therapeutic agents
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins
US4181729A (en) * 1979-03-21 1980-01-01 Pfizer Inc. Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives

Also Published As

Publication number Publication date
EP0034063A1 (en) 1981-08-19
US4248882A (en) 1981-02-03
DK156400C (da) 1990-01-08
ATE3865T1 (de) 1983-07-15
IE810261L (en) 1981-08-12
GR73856B (2) 1984-05-08
IE50895B1 (en) 1986-08-06
EP0034063B1 (en) 1983-06-22
JPS56127379A (en) 1981-10-06
DE3160449D1 (en) 1983-07-28
DK156400B (da) 1989-08-14
DK56581A (da) 1981-08-13

Similar Documents

Publication Publication Date Title
JPS6237636B2 (2)
CA1088073A (en) Hydantoin therapeutic agents
US4855298A (en) 6-Halo-1,2,3,4-tetrahydroquinazoline-4-spiro-4-imidazolidine-2,2'5'-triones useful for the treatment and prophylaxis of diabetic complications
US9403846B2 (en) Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US4283539A (en) Isoquinoline acetic acids
EP0833822A1 (fr) Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2734265A1 (fr) Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
EP0306408A1 (fr) Imidazo[1,2b]pyridazines, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4575507A (en) Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use
CA1117944A (fr) Procedes de preparation de nouvelles piperazines disubstituees
KR860001581B1 (ko) 스피로-3-헤테로-아졸론의 제조방법
CA1244443A (en) Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complications
US4464380A (en) Imidazolidinedione derivatives
US4474967A (en) 8-Deutero and 8-tritio-substituted derivatives of D-4S-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione
US4868315A (en) Novel aryloxycycloalkanolaminoalkylene aryl ketones
JPS61109789A (ja) スピロ‐ヘテロアゾロン化合物類
US4533667A (en) Imidazolidinedione derivatives
JPS582955B2 (ja) スピロ−キノロンヒダントイン類
US4766141A (en) Spiro-succinimides for treatment of diabetes complications
FR2673944A1 (fr) Derives de l'1,8-naphtalimide, leur procede de preparation et les compositions pharmaceutiques les contenant.
CN118930553A (zh) 5,6,7,8-四氢呋喃[3,4-g]异喹啉-3(1H)-酮化合物及其制备方法、药物组合物和用途
CN118930552A (zh) 异苯并呋喃-1(3h)-酮类化合物及其制备方法、药物组合物和用途
JPH0465832B2 (2)